Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

The Value of Innovation

The Value of Innovation

In 2001, the National Pharmaceutical Council provided funding for the September/October issue of Health Affairs, which focused on the value of innovation. The issue showcased a growing body of research that examines the value of pharmaceuticals and other medical innovations.

Descriptions of some of the key articles from this issue follow:

Are the Benefits of Newer Drugs Worth Their Cost? Evidence From the 1996 MEPS

Author: Lichtenberg, FR.

This study analyzes data on prescribed medicines from the 1996 Medical Expenditure Panel Survey (MEPS), a nationally representative database on the use of health care services and spending, to examine the association between the use of newer medicines and morbidity, mortality, and health spending. According to the findings, people consuming newer drugs were significantly less likely to die by the end of the survey and were significantly less likely to experience work-loss days than were people consuming older drugs. The most notable finding, however, is that use of newer drugs tends to lower all types of nondrug medical spending, resulting in a substantial net reduction in the total cost of treating a given condition.

Is Technological Change in Medicine Worth It?

Authors: Cutler, DM; McClellan, M.

This article explores the relationship between spending and health benefits. They analyze technical change in five medical conditions to determine whether or not the benefits of medical advances exceed the costs in those diseases. In four of five conditions examined -- heart attacks, low-birthweight infants, depression, and cataracts -- benefits outweighed costs, and in the fifth condition, breast cancer, costs and benefits were equal. Putting a price on life is a difficult task, but the authors calculate that the true cost of some types of care is actually falling because of medical innovation.

Link Between Gross Profitability and Pharmaceutical R&D Spending

Authors: Scherer, FM.

This analysis focuses on the question: What does the pharmaceutical industry really do with its profits? The answer is that the new pharmaceutical discoveries benefiting consumers are being driven by the gross profit margins that pharmaceutical companies make. As profits increase, so does research and development. This ultimately yields new and promising options for consumers. In addition, the author finds that medical innovations are leading to longer life and improved quality of life.

Perspectives on the Pharmaceutical Industry

Authors: Reinhardt, UE.

This paper provides an economic perspective on the pharmaceutical industry, which has come under increasing criticism on a number of issues. Much of the criticism is based on inaccurate perceptions, and suggests that our nation can indeed afford spending on drugs that help us live longer, more productive lives. Spending on pharmaceuticals accounts for only a small fraction of our Gross Domestic Product (GDP). In fact, Americans spend more per capita on alcohol, tobacco, and entertainment combined than on pharmaceuticals.

Price of Progress: Prescription Drugs in the Health Care Market

Kleinke, JD.
Increased spending on pharmaceuticals does not explain the insurance premium increases that many consumers are seeing. The author points out that pharmaceuticals are a small fraction of the total equation, and that even though spending on pharmaceuticals is increasing, that rise in expenditures amounts to a small percentage of the premium increases.

Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Newsletter Volume

E.V.I.dently November 2015

MessageCan We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?Has biopharmaceutical innovation brought value and made a...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

Pharmaceutical Innovation’s Role in the Panorama of Health System Improvement and Population Health

When he announced the launch of the White House Precision Medicine Initiative, President Obama said, “If we have the opportunity to prevent hurt and...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

National Pharmaceutical Council Welcomes Amgen as Its Newest Member

Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...
Press Release

National Pharmaceutical Council Expands Policy and Research Staff

WASHINGTON, DC (January 4, 2012) -- The National Pharmaceutical Council (NPC) announced the hiring of Daryl Pritchard, PhD, as the Director of...
Press Release

New NPC Report Provides Guidance on Evaluating Comparative Effectiveness Studies

WASHINGTON, D.C. (December 10, 2009) – A new report released today by the National Pharmaceutical Council (NPC) provides guidance in the evaluation...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Health Care Reform and Pharmaceutical Innovation

Although the Patient Protection and Affordable Care Act of 2010 (PPACA) is expected to have broad societal benefits, moving forward, it will be...
YouTube Videos

CER and Its Impact on Pharma Innovation

Dr. Darius Lakdawalla, director of research at the Schaeffer Center for Health Policy and Economics at the University of Southern California,...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

Pharmaceutical Innovation’s Role in the Panorama of Health System Improvement and Population Health

When he announced the launch of the White House Precision Medicine Initiative, President Obama said, “If we have the opportunity to prevent hurt and...
Blog Post

At the HHS Pharmaceutical Forum, We Need to Consider All Health Care Costs

On November 20, stakeholders will come together for a day-long event—“HHS Pharmaceutical Forum: Innovation, Access, Affordability and Better Health”—...
Blog Post

Value Is in the Eye of the Beholder? NPC Takes Closer Look at ICER Framework

In recent months, a number of health organizations have developed “value assessment frameworks,” which are designed to inform coverage and treatment...

The Productivity Crisis in Pharmaceutical R&D

Although investment in pharmaceutical R&D has increased substantially in this time, the lack of...

Framing the Debate- Untangling the Potential Impact of Comparative Effectiveness Research on Innovation

Researchers integrated expert insight from a roundtable discussion into their own market research...
  •  
  • 1 of 4
  • >